TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women.
|ClinicalTrials.gov Identifier: NCT00739622|
Recruitment Status : Completed
First Posted : August 22, 2008
Last Update Posted : April 28, 2010
|Condition or disease||Intervention/treatment||Phase|
|HIV AIDS Oral Contraceptive||Drug: TMC278||Phase 1|
Human immunodeficiency virus (HIV)-infected patients are routinely being treated with combinations of 3 or 4 drugs (highly active antiretroviral therapy [HAART]), to reduce the risk of viral resistance development. Development of new potent antiretroviral (ARV) drugs is urgently needed to prolong suppression of viral replication in patients infected with HIV. This is a Phase I, open-label trial in healthy women to investigate the pharmacokinetic interaction between the combination of ethinylestradiol and norethindrone and TMC278 25 mg once daily. The trial aims to allow further recommendations regarding the concurrent use of oral contraceptives and TMC278. The trial population will consist of 18 healthy women who are stable on oral contraceptives (OC), specifically ethinylestradiol and norethindrone, or who, if they are not currently using this OC, are willing to start or switch to this OC for the duration of the study.
Healthy volunteers will receive the OC once daily for 21 days for at least 1 OC cycle prior to Day 1 [stabilizing OC cycle from Day -28 to Day -1]. During the second OC cycle [from Day 1 to Day 28], subjects will receive the OC alone once daily for 21 days [Treatment A]. During the third OC cycle [from Day 29 to 56], subjects will receive the OC once daily for 21 days and in addition TMC278 25 mg q.d. in the morning for 15 days, starting on the first day of OC intake (Day 29) [Treatment B]. Full 24-hour pharmacokinetic profiles of ethinylestradiol and norethindrone will be determined after the first 2 weeks of the second OC cycle (Treatment A: OC alone; Day 15) and after the first 2 weeks of the third OC cycle (Treatment B: OC+TMC278; Day 43). A full 24-hour pharmacokinetic profile of TMC278 will be determined on Day 43. Blood samples on these days will be drawn just before drug intake (predose), and at 0.5, 1, 1.5, 2, 3, 4, 5 (Day 43 only), 6, 9, 12, 16 (Day 43 only) and 24 hours postdose. Safety evaluations include evaluation of adverse events, physical examination including vital signs, ECGs and laboratory hematology and biochemistry assessments. Healthy volunteers will receive a tablet of ethinylestradiol and norethindrone OC once daily for 21 days for at least 1 OC cycle prior to Day 1. During the second OC cycle, healthy volunteers will receive a tablet of ethinylestradiol and norethindrone OC alone once daily for 21 days. During the third OC cycle, healthy volunteers will receive a tablet of ethinylestradiol and norethindrone once daily for 21 days and in addition a tablet of TMC278 25 mg once daily in the morning for 15 days.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||18 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I, Open-label Drug-drug Interaction Trial to Investigate the Effect of TMC278 25 mg q.d. on the Steady State Pharmacokinetics of Ethinylestradiol and Norethindrone, in Healthy Women|
|Study Start Date :||July 2008|
|Primary Completion Date :||December 2008|
|Study Completion Date :||December 2008|
- The primary objective of this study is to determine the effect of steady-state concentrations of TMC278 25 mg once daily on the steady-state pharmacokinetics of ethinylestradiol 35 mcg and norethindrone 1 mg once daily.
- The secondary objective of this study is to evaluate the short-term safety and tolerability of coadministration of TMC278 and ethinylestradiol and norethindrone OC in healthy women.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00739622
|Study Director:||Tibotec Pharmaceuticals Limited Clinical Trial||Tibotec Pharmaceutical Limited|